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Abstract 
Background: The SAKK 19/05 trial investigated the safety and efficacy of the combined targeted therapy bevaci-
zumab and erlotinib (BE) in unselected patients with advanced non-squamous non-small cell lung cancer (NSCLC). 
Although activating EGFR mutations were the strongest predictors of the response to BE, some patients not harbor-
ing driver mutations could benefit from the combined therapy. The identification of predictive biomarkers before or 
short after initiation of therapy is therefore paramount for proper patient selection, especially among EGFR wild-types. 
The first aim of this study was to investigate the early change in blood gene expression in unselected patients with 
advanced non-squamous NSCLC treated by BE. The second aim was to assess the predictive value of blood gene 
expression levels at baseline and 24h after BE therapy.
Methods: Blood samples from 43 advanced non-squamous NSCLC patients taken at baseline and 24h after initiation 
of therapy were profiled using Affymetrix’ exon arrays. The 24h gene dysregulation was investigated in the light of 
gene functional annotations using gene set enrichment analysis. The predictive value of blood gene expression levels 
was assessed and validated using an independent dataset.
Results: Significant gene dysregulations associated with the 24h-effect of BE were detected from blood-based 
whole-genome profiling. BE had a direct effect on “Pathways in cancer”, by significantly down-regulating genes 
involved in cytokine–cytokine receptor interaction, MAPK signaling pathway and mTOR signaling pathway. These 
pathways contribute to phenomena of evasion of apoptosis, proliferation and sustained angiogenesis. Other signal-
ing pathways specifically reflecting the mechanisms of action of erlotinib and the anti-angiogenesis effect of beva-
cizumab were activated. The magnitude of change of the most dysregulated genes at 24h did not have a predictive 
value regarding the patients’ response to BE. However, predictive markers were identified from the gene expression 
levels at 24h regarding time to progression under BE.
Conclusions: The 24h-effect of the combined targeted therapy BE could be accurately monitored in advanced non-
squamous NSCLC blood samples using whole-genome exon arrays. Putative predictive markers at 24h could reflect 
patients’ response to BE after adjusting for their mutational status.
Trial registration ClinicalTrials.gov: NCT00354549
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Background
Combined targeted therapies represent novel therapeu-
tic approaches simultaneously acting on several specific 
molecular pathways in cancer and having a number of 
advantages over standard single-targeted agents [1, 2].
Several trials have shown the beneficial effect of epi-
dermal growth factor receptor tyrosine kinase inhibi-
tors (EGFR-TKIs) in advanced non-small cell lung cancer 
patients (NSCLC) harboring activating EGFR mutations 
leading to the adoption of EGFR-TKI as standard treat-
ment in this population [3, 4]. Preclinical studies sug-
gested that the combination of an EGFR-TKI together 
with an angiogenesis inhibitor (e.g. targeting the vascu-
lar endothelial growth factor VEGF) can have a syner-
gistic effect [5, 6]. Recent clinical trials showed superior 
efficacy of the combined anti-angiogenesis bevacizumab 
(B) with the TKI erlotinib (E) in EGFR mutated patients 
compared to E alone [7, 8]. More specifically, these trials 
showed that first line treatments combining BE improved 
the progression free survival (PFS)—but not overall sur-
vival (OS)—of patients harboring an EGFR driver muta-
tion in comparison with E alone [7, 9].
In unselected patients, BE had better PFS than E alone 
without improvement of survival in recurrent NSCLC 
suggesting moderate activity of BE [6]. As first line ther-
apy in unselected patients, the overall response rate of 
BE was 12%, whereas PFS was 3.5  months, again show-
ing moderate activity [10]. Despite the favorable toxicity 
profile of BE, these results are inferior to chemotherapy 
first line or immunotherapy second line. The SAKK 19/05 
trial from the Swiss Group for Clinical Cancer Research 
showed that first-line combined BE treatment followed 
by chemotherapy regimen is feasible with acceptable 
toxicity and activity in an unselected advanced non-
squamous NSCLC population [11]. On the other hand, 
the phase II TASK study did not show a benefit in terms 
of PFS for the combination BE in unselected first line 
advanced non-squamous NSCLC compared with chemo-
therapy plus B [10, 12].
Although the presence of EGFR mutations is the 
strongest predictor of the response to anti-EGFR-TKI, 
a recent meta-analysis showed that wild-type EGFR 
patients can benefit from the therapy with an improved 
OS compared with placebo or standard chemotherapy 
[hazard ratio = 0.780 (95% CI 0.654–0.930)] [13]. There-
fore, the identification of very early predictive markers 
of multiple targeted therapies and the understanding of 
their mechanisms of action in advanced non-squamous 
NSCLC is of paramount importance in order to better 
identify subsets of patients who may still benefit from 
these treatments.
Blood-based biomarkers in NSCLC are of particular 
interest as they can be easily and non-invasively accessed 
[14]. Whole-genome exon arrays provide an ideal plat-
form for the discovery of novel putative biomarkers by 
investigating expression variations at an exon-level reso-
lution [15]. More specifically, exon arrays allow analyses 
both at the gene and at the exon level. Exon-level analy-
ses are usually performed to detect alternative splicing 
events [16].
The aim of the current study was to analyze blood-level 
exon array profiling data from unselected patients with 
advanced non-squamous NSCLC before and 24h after 
initiation of the combined targeted therapy BE. The spe-
cific objectives are twofold: (1) uncover which genes from 
whole blood circulating RNAs are immediately impacted 
by the effect of the combined therapy BE, and (2) assess 
the predictive value of these dysregulations.
Methods
Lung cancer dataset
The gene expression data set originated from a transla-
tional substudy of the phase II SAKK 19/05 trial from the 
Swiss Group for Clinical Cancer Research (ClinicalTrials.
gov: NCT00354549). In the original study, 103 unselected 
patients with advanced non-squamous NSCLC were 
enrolled, among which 101 were evaluable. The experi-
mental design of the trial SAKK 19/05 is summarized in 
Fig. 1. Patients were treated using the combined targeted 
therapy BE until disease progression or unacceptable tox-
icity. At progression, standard platinum-based chemo-
therapy (CT) was used. The primary endpoint of this 
trial was disease stabilization 12  weeks after initiation 
of therapy. Secondary endpoints included tumor shrink-
age at 12  weeks (TS12), time to progression under BE 
(TTPBE), time to progression under CT (TTPCT) and 
OS. Further detailed information about this trial can be 
found in previous publications [11, 17, 18]. As part of a 
Fig. 1 Treatment scheme of the SAKK 19/05 trial. Patients received BE until progression or unacceptable toxicity. Upon disease progression, patients 
received standard chemotherapy with cisplatin and gemcitabine
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translational substudy, blood samples were taken at base-
line and 24h after initiation of treatment for gene expres-
sion analysis in a subset of 49 patients. The current study 
was approved by the ethics committee of the canton St. 
Gallen (EKSG 06/012).
Exon array analysis
RNA from whole blood samples was extracted and qual-
ity checked. Six pairs of samples had to be excluded from 
the analysis due to low quality, whereas RNA extracts 
provided sufficient quality for microarray hybridization 
in 43 out of 49 pairs of sample. Messenger RNAs were 
hybridized on Affymetrix Human Exon 1.0 ST arrays 
(Affymetrix, Santa Clara, CA, USA) following stand-
ard recommendations from the manufacturer. This 
microarray platform measures genome-wide exon-level 
expression in over 1.4 million probe sets, and allows the 
investigation of genomic variations both at the gene and 
at the exon level. For the sake of this analysis, 439,778 
exonic probe sets (within 38,900 genes) were kept in the 
analysis, after filtering out intronic, intergenic and unre-
liable probe sets (according to the nomenclature defined 
in the R package annmap [19]). Raw data (Affymetrix 
CEL files) have been deposited in NCBI’s Gene Expres-
sion Omnibus (GEO), and are accessible through GEO 
Series accession number GSE61676. The exon level probe 
sets were pre-processed, quality checked and normalized 
using the RMA procedure (including background correc-
tion, quantile normalization and median-polish summari-
zation) as implemented in the R package oligo [20, 21].
Statistical considerations
The current experimental design includes a repeated 
measurement of genome-wide exon-level expressions 
in 43 patients at two different time points (baseline and 
24h after initiation of therapy). The exon expression data 
are stored in a pair of fully matched tables. Dually con-
strained correspondence analysis (DCCA)—an exten-
sion of the multivariate technique correspondence 
analysis—was used to investigate the 24h-change in exon 
expression levels [16]. DCCA uses observation- and vari-
able-wise linear constraints in order to take into account 
complex experimental designs including within-patient 
repeated measurements and variables grouped into hier-
archical levels (within-gene exonic structures). The theo-
retical scheme of DCCA as applied to our experimental 
design is summarized in Fig. 2. The mathematical under-
pinnings of DCCA are further described in Additional 
file  1. In the current work, the following parametriza-
tion of DCCA was used: (1) the two fully matched tables 
of exon-level expression intensities at baseline and 24h 
were stacked observation-wise; (2) an observation-wise 
between-time constraint (baseline vs. 24h) was applied 
after partialling out the within-patient effect; (3) a vari-
able-wise constraint indicating the within-gene exonic 
structure was applied.
Generalized linear (mixed effects) models were used 
in order to test the predictive value of the identified 
biomarkers. Binary endpoints were tested using logis-
tic regression, time to event data were modeled using 
Cox proportional hazards regression, and continuous 
Fig. 2 Design of experiment and scheme of dually constrained correspondence analysis. Two matched tables X and Y are analyzed by DCCA. The 
2 tables are rearranged into one stacked table. Additional external information on both rows and columns are used as positive and/or negative 
constraints
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variables were modeled using (multiple) linear regres-
sion. Mixed effects modeling was used when testing 
associations in the frame of the within-patient repeated 
measurement design. The adjustment for patients’ EGFR 
mutational status was done by including the mutational 
status as covariate in the predictive models. The signifi-
cance level used for the discovery of the putative predic-
tive markers was set to 0.001. Gene signatures combining 
the information of the best predictive candidates were 
built using the metagene approach [22]. In this approach, 
the linear combination of several genes is calculated as 
follows: (1) The matrix of normalized gene expression 
intensities for all patients at a given time point (rows) 
and for all candidate genes (columns) is analyzed using 
unscaled principal component analysis (PCA); (2) The 
row coordinates (scores) on the first PCA axis summariz-
ing the largest amount of variance are extracted (meta-
gene score); (3) Based on the median of the metagene 
score, a binary score is created to discriminate between 
low versus high-risk patients.
Computational considerations
All analyses were implemented using the R statistical 
software [23] including the extension package ade4 [24], 
as well as dedicated packages from the Bioconductor 
project [25] such as the package oligo for microarray 
preprocessing [21] and the annotation package annmap 
(Homo sapiens database version 86). Functions avail-
able in ade4 (including dudi.coa, wca, bca, pcaiv 
and pcaivortho) can theoretically be used to carry 
out DCCA. However, for reasons of computational effi-
ciency due to the extensive size of exon array datasets, 
the DCCA algorithm was substantially optimized and 
a new R extension package dcca is available (see Addi-
tional file 1). Hypothesis testing for the identification of 
predictive biomarkers was carried out using the following 
R packages: lme4, coxme and multcomp.
Gene functional annotations and validations
Gene set enrichment analysis was done by interrogating 
the molecular knowledge databases Kyoto Encyclopedia 
of Genes and Genomes (KEGG) [26] and WikiPathways 
[1] using the functional annotation web-service WebGe-
stalt [27]. Enrichment analyses were based on the list of 
100 most dysregulated genes (as identified by DCCA), 
as well as the lists of genes which were significantly pre-
dicting patient’s outcome (each of the investigated end-
points). The significance of the enrichment was obtained 
using hypergeometric tests. Validation was carried out 
using the lung data set from the Kaplan–Meier Plot-
ter (KMplotter) web tool [28]. KMplotter is a manually 
curated database including gene expression level infor-
mation about more than 50,000 Affymetrix probe set IDs 
together with associated clinical information. The prog-
nostic value of single or multiple genes can be assessed 
with regard to relapse free and overall survival. Another 
independent lung cancer dataset was used for exter-
nal validation. This gene expression microarray dataset 
includes 85 lung adenocarcinoma tumor samples and 
is part of the program “Carte d’Identité des Tumeurs” 
(CIT) from the french national cancer league [29]. Sam-
ples were profiled using the Affymetrix Human Genome 
U133 Plus 2.0 Array and raw data are available in NCBI’s 
Gene Expression Omnibus through GEO Series acces-
sion number GSE30219. Furthermore, the results were 
discussed in the light of available literature findings.
Results
Patients characteristics
The characteristics of the 43 patients are reported in 
Table 1. Patients were late stage (91% stage IV/9% stage 
IIIb) non-squamous NSCLC. Five out of 43 patients 
had demonstrable EGFR mutations: one on exon 18 
(E709A-G719S), three on exon 19 (Del L747-G749, Del 
E746-A750 and R748-S752) and one on exon 21 (L858R). 
The median age was 61 years old (IQR 54–66) and the sex 
ratio was 0.44 (19 males/24 females). Disease stabilization 
at 12 weeks was reached in 53% of patients. The median 
tumor shrinkage at 12  weeks was 15.8%. The median 
overall survival was 11.1 (95% CI 10.1–17.9) months. The 
median time-to-progression under BE was 4.0 (95% CI 
2.8–6.0)  months, whereas the median time-to-progres-
sion under CT was 2.6 (95% CI 1.7–5.7) months.
24h gene dysregulation
The 100 genes mostly dysregulated (54 up-regulated vs. 
46 down-regulated) by the 24h effect of BE are summa-
rized in Table   2. The genes were involved in all aspects 
Table 1 Patients characteristics
The table summarizes the characteristics of the 43 patients included in the study
Variables
Number of patients (n) 43
Age (median [range]) 61 (35–78)
Gender (# male [%]) 19 (44.2%)
Stage (n [%]) IIIb: 4 (9.3%); IV: 39 (90.7%)
Demonstrable EGFR mutations (n [%]) 5 (11.6%)
Disease stabilization at 12 weeks (n [%]) 23 (53.5%)
Tumor shrinkage at 12 weeks (median [IQR]), 
in % of tumor size at baseline
15.8% (−2.5 to 26.2%)
Median overall survival (95% CI), in months 11.1 (10.1–17.9)
Median time-to-progression under  
BE (95% CI), in months
4.0 (2.8–6.0)
Median time-to-progression under  
CT (95% CI), in months
2.6 (1.7–5.7)
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Table 2 List of the 100 most dysregulated genes due to the 24h effect of BE
Ensembl Gene symbol Description Gene dysregulation at 24h
ENSG00000125257 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Up-regulated
ENSG00000114770 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 Down-regulated
ENSG00000173208 ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 Up-regulated
ENSG00000151726 ACSL1 Acyl-CoA synthetase long-chain family member 1 Down-regulated
ENSG00000135074 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) Down-regulated
ENSG00000154027 AK5 Adenylate kinase 5 Up-regulated
ENSG00000151150 ANK3 Ankyrin 3, node of Ranvier (ankyrin G) Up-regulated
ENSG00000206560 ANKRD28 Ankyrin repeat domain 28 Up-regulated
ENSG00000118520 ARG1 Arginase, liver Down-regulated
ENSG00000196914 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 Up-regulated
ENSG00000156802 ATAD2 ATPase family, AAA domain containing 2 Up-regulated
ENSG00000085224 ATRX Alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. 
cerevisiae)
Up-regulated
ENSG00000023445 BIRC3 baculoviral IAP repeat-containing 3 Up-regulated
ENSG00000102010 BMX BMX non-receptor tyrosine kinase Down-regulated
ENSG00000136492 BRIP1 BRCA1 interacting protein C-terminal helicase 1 Up-regulated
ENSG00000197603 C5orf42 Chromosome 5 open reading frame 42 Up-regulated
ENSG00000152495 CAMK4 Calcium/calmodulin-dependent protein kinase IV Up-regulated
ENSG00000137812 CASC5 Cancer susceptibility candidate 5 Up-regulated
ENSG00000138778 CENPE Centromere protein E, 312 kDa Up-regulated
ENSG00000198707 CEP290 Centrosomal protein 290 kDa Up-regulated
ENSG00000106034 CPED1 Cadherin-like and PC-esterase domain containing 1 Up-regulated
ENSG00000103196 CRISPLD2 Cysteine-rich secretory protein LCCL domain containing 2 Down-regulated
ENSG00000146122 DAAM2 Dishevelled associated activator of morphogenesis 2 Down-regulated
ENSG00000035664 DAPK2 Death-associated protein kinase 2 Down-regulated
ENSG00000137628 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 Up-regulated
ENSG00000174485 DENND4A DENN/MADD domain containing 4A Up-regulated
ENSG00000135905 DOCK10 Dedicator of cytokinesis 10 Up-regulated
ENSG00000147459 DOCK5 Dedicator of cytokinesis 5 Down-regulated
ENSG00000088387 DOCK9 Dedicator of cytokinesis 9 Up-regulated
ENSG00000178904 DPY19L3 Dpy-19-like 3 (C. elegans) Down-regulated
ENSG00000134765 DSC1 Desmocollin 1 Up-regulated
ENSG00000135636 DYSF Dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) Down-regulated
ENSG00000198919 DZIP3 DAZ interacting protein 3, zinc finger Up-regulated
ENSG00000102189 EEA1 Early endosome antigen 1 Up-regulated
ENSG00000151491 EPS8 Epidermal growth factor receptor pathway substrate 8 Up-regulated
ENSG00000089048 ESF1 ESF1, nucleolar pre-rRNA processing protein, homolog (S. cerevisiae) Up-regulated
ENSG00000198734 F5 Coagulation factor V (proaccelerin, labile factor) Down-regulated
ENSG00000140525 FANCI Fanconi anemia, complementation group I Up-regulated
ENSG00000138829 FBN2 Fibrillin 2 (congenital contractural arachnodactyly) Down-regulated
ENSG00000139132 FGD4 FYVE, RhoGEF and PH domain containing 4 Down-regulated
ENSG00000122025 FLT3 Fms-related tyrosine kinase 3 Down-regulated
ENSG00000161791 FMNL3 Formin-like 3 Up-regulated
ENSG00000073910 FRY Furry homolog (Drosophila) Down-regulated
ENSG00000162654 GBP4 Guanylate binding protein 4 Up-regulated
ENSG00000182885 GPR97 G protein-coupled receptor 97 Down-regulated
ENSG00000106070 GRB10 Growth factor receptor-bound protein 10 Down-regulated
ENSG00000084110 HAL Histidine ammonia-lyase Down-regulated
ENSG00000120694 HSPH1 Heat shock 105/110 kDa protein 1 Up-regulated
ENSG00000140443 IGF1R Insulin-like growth factor 1 receptor Down-regulated
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Table 2 continued
Ensembl Gene symbol Description Gene dysregulation at 24h
ENSG00000197081 IGF2R Insulin-like growth factor 2 receptor Down-regulated
ENSG00000115604 IL18R1 Interleukin 18 receptor 1 Down-regulated
ENSG00000115594 IL1R1 Interleukin 1 receptor, type I Down-regulated
ENSG00000115590 IL1R2 Interleukin 1 receptor, type II Down-regulated
ENSG00000109452 INPP4B Inositol polyphosphate-4-phosphatase, type II, 105 kDa Up-regulated
ENSG00000102445 KIAA0226L KIAA0226-like Down-regulated
ENSG00000137261 KIAA0319 KIAA0319 Down-regulated
ENSG00000110318 KIAA1377 KIAA1377 Up-regulated
ENSG00000054523 KIF1B Kinesin family member 1B Down-regulated
ENSG00000138182 KIF20B Kinesin family member 20B Up-regulated
ENSG00000139116 KIF21A Kinesin family member 21A Up-regulated
ENSG00000068796 KIF2A Kinesin heavy chain member 2A Up-regulated
ENSG00000184445 KNTC1 Kinetochore associated 1 Up-regulated
ENSG00000126777 KTN1 Kinectin 1 (kinesin receptor) Up-regulated
ENSG00000123384 LRP1 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) Down-regulated
ENSG00000186205 MARC1 Mitochondrial amidoxime reducing component 1 Down-regulated
ENSG00000257335 MGAM Maltase-glucoamylase (alpha-glucosidase) Down-regulated
ENSG00000171843 MLLT3 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); 
translocated to, 3
Up-regulated
ENSG00000196549 MME Membrane metallo-endopeptidase Down-regulated
ENSG00000100985 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV col-
lagenase)
Down-regulated
ENSG00000051825 MPHOSPH9 M-phase phosphoprotein 9 Up-regulated
ENSG00000138119 MYOF Myoferlin Up-regulated
ENSG00000049759 NEDD4L Neural precursor cell expressed, developmentally down-regulated 4-like Up-regulated
ENSG00000184613 NELL2 NEL-like 2 (chicken) Up-regulated
ENSG00000173145 NOC3L Nucleolar complex associated 3 homolog (S. cerevisiae) Up-regulated
ENSG00000179299 NSUN7 NOL1/NOP2/Sun domain family, member 7 Down-regulated
ENSG00000111581 NUP107 Nucleoporin 107 kDa Up-regulated
ENSG00000159339 PADI4 Peptidyl arginine deiminase, type IV Down-regulated
ENSG00000123836 PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 Down-regulated
ENSG00000075651 PLD1 Phospholipase D1, phosphatidylcholine-specific Down-regulated
ENSG00000101868 POLA1 Polymerase (DNA directed), alpha 1 Up-regulated
ENSG00000080839 RBL1 Retinoblastoma-like 1 (p107) Up-regulated
ENSG00000257743 RP11-1220K2.2 Putative inactive maltase-glucoamylase-like protein LOC93432 Down-regulated
ENSG00000226891 RP11-182I10.3 Uncharacterized LOC101927084 Down-regulated
ENSG00000258476 RP11-76E17.3 NA Down-regulated
ENSG00000140386 SCAPER S phase cyclin A-associated protein in the ER Up-regulated
ENSG00000018280 SLC11A1 Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 
1
Down-regulated
ENSG00000140090 SLC24A4 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 Down-regulated
ENSG00000112053 SLC26A8 Solute carrier family 26, member 8 Down-regulated
ENSG00000157800 SLC37A3 Solute carrier family 37 (glycerol-3-phosphate transporter), member 3 Down-regulated
ENSG00000136824 SMC2 Structural maintenance of chromosomes 2 Up-regulated
ENSG00000163029 SMC6 Structural maintenance of chromosomes 6 Up-regulated
ENSG00000009694 TENM1 Teneurin transmembrane protein 1 Down-regulated
ENSG00000169902 TPST1 Tyrosylprotein sulfotransferase 1 Down-regulated
ENSG00000198677 TTC37 Tetratricopeptide repeat domain 37 Up-regulated
ENSG00000155657 TTN Titin Up-regulated
ENSG00000120800 UTP20 UTP20, small subunit (SSU) processome component, homolog (yeast) Up-regulated
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of tumor biology. This includes genes involved in mitosis 
and cell cycle processes such as the cancer susceptibility 
candidate 5 (CASC5) encoding for a protein influenc-
ing the spindle assembly checkpoint during eukaryotic 
cell cycle; the centromere-associated protein E (CENPE) 
which accumulates and play a key stabilizing role during 
mitosis; the protein furry homolog (FRY) which plays a 
crucial role in the structural integrity of mitotic cen-
trosomes; kinetochore associated 1 (KNTC1) encoding 
for a protein ensuring proper chromosome segregation 
during cell division; Phospholipase D1 (PLD1) involved 
in cancer progression [30] and in the regulation of mito-
sis in relationship with the “Ras signaling pathway” and 
“Pathways in cancer”. Other dysregulated genes were 
involved in energy-dependent metabolisms (ATPase/
GTPase). This includes genes from the ATPase Family 
(ATAD2) known to be related to gastric cancer network, 
and which may play an important role in cell proliferation 
and cell cycle progression of breast cancer cells; Gua-
nylate Binding Protein 4 (GBP4) related to GTPase activ-
ity and associated with the interferon signaling pathway; 
dedicator of cytokinesis 10 (DOCK10) acting on GTPase 
and related to hemostasis and regulation of cell division 
cycle 42 (CDC42) activity. Mechanisms of cell migra-
tion are also controlled by a series of dysregulated genes 
such as ADAM Metallopeptidase Domain 19 (ADAM19) 
regulating cell migration, cell adhesion and cell-cell/cell-
matrix interactions, supposed to play an important role 
in pathological processes including cancer; BMX non-
receptor tyrosine kinase (BMX) encoding for a protein 
implicated in several signal transduction pathways regu-
lating tumorigenicity of cancer cells; Epidermal Growth 
Factor Receptor Pathway Substrate 8 (EPS8) encoding 
for a protein having functions in part of the EGFR path-
way and being related to Tyrosine Kinases/Adaptors and 
Development FGFR signaling pathways; Fms-Related 
Tyrosine Kinase 3 (FLT3) encoding for a class III recep-
tor tyrosine kinase regulating hematopoiesis, and whose 
action is related to apotosis, proliferation and differen-
tiation processes; Interleukin 1 Receptor, Type II (IL1R2) 
controling many cellular functions including prolifera-
tion, differentiation, and cell survival/apoptosis; Matrix 
Metallopeptidase 9 (MMP9) involved in tissue/matrix 
remodeling, playing a central role in cell proliferation, 
migration, differentiation, showing an altered expression 
in a number of different human cancers with poor prog-
nosis. Apoptosis was regulated through the action of var-
ious genes including baculoviral IAP repeat containing 3 
(BIRC3) encoding for an inhibitor of apoptosis protein 
acting on killing tumor cells; death-associated protein 
kinase 2 (DAPK2) whose overexpression was shown to 
induce cell apoptosis; Retinoblastoma-Like 1 (RBL1) 
encoding for a tumor suppressor protein involved in 
cell cycle regulation; insulin-like growth factor 1 recep-
tor (IGF1R) encoding for a growth factor with tyrosine 
kinase activity, having an anti-apoptotic effect and being 
highly overexpressed in most malignant tissues [31].
Based on the 100 best candidates identified by DCCA, 
three main pathways (according to the KEGG functional 
annotation database) were significantly altered by the 
24h effect of the combined therapy BE: Hematopoietic 
cell lineage (KEGG pathway hsa04640; p = 0.0094); ABC 
transporters (KEGG pathway hsa02010; p = 0.0085 ); 
Pathways in cancer (KEGG pathway hsa05200; 
p = 0.0204).
Figure  3 displays the gene expression levels of each 
genes (baseline and 24h) within these dysregulated path-
ways. Figure  4 shows the detailed KEGG’s “Pathways in 
Cancer” highlighting the down-regulated genes within 
the sub-pathways “Cytokine–cytokine receptor informa-
tion” and “MAPK signaling pathways”. The down-regula-
tion of these sub-pathways contributes to the limitation 
of cell proliferation.
These pathway dysregulations are well in line with the 
expected effects of both erlotinib (“Pathways in can-
cer”; “ABC transporters”) and bevacizumab (“Hemat-
opoietic cell lineage”). “Pathways in cancer” is a generic 
pathway, including genes involved in various aspects of 
tumorigenesis such as phenomena of proliferation, inva-
sion, resistance and apoptosis. Several diseases are inter-
related to this pathway, including non-small cell lung 
cancer. Most genes from the “Pathways in cancer” (FLT3, 
IGF1R, DAPK2, PLD1 and MMP9) are inhibited due to 
the action of BE resulting in an anti-proliferative and 
pro-apoptotic action of the combined therapy, with the 
notable exception of the up-regulation of the apoptosis 
inhibitor BIRC3. The combined action of BE results in the 
inhibition of all genes that belong to the “Hematopoietic 
Table 2 continued
Ensembl Gene symbol Description Gene dysregulation at 24h
ENSG00000197969 VPS13A Vacuolar protein sorting 13 homolog A (S. cerevisiae) Up-regulated
ENSG00000163625 WDFY3 WD repeat and FYVE domain containing 3 Down-regulated
ENSG00000213799 ZNF845 Zinc finger protein 845 Up-regulated
ENSG00000167232 ZNF91 Zinc finger protein 91 Up-regulated
Information includes the Ensembl code, the gene symbol, description and sign of dysregulation. For convenience, the genes are ordered alphabetically
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cell lineage” (FLT3, IL1R1, IL1R2, MME). Hematopoietic 
stem cells play important roles for angiogenesis [32]. The 
down-regulation of genes within the pathway “Hemat-
opoietic cell lineage” may be related to the specific anti-
angiogenic action of bevacizumab [33, 34]. On the other 
hand, the dysregulation of genes that belong to the path-
way “ABC transporters” is probably associated with the 
energy-related mechanisms of action of erlotinib [35, 36].
Gene set enrichment analysis based on the WikiPath-
ways database provides information on additional can-
cer- and energy-related activated pathways including 
“gastric cancer network 2” (WP2363, p = 0.010), “IL1 
megakaryocytes in obesity” (WP2865, p = 0.006), “apop-
tosis modulation and signaling” (WP1772, P = 0.011) 
and “gastric cancer network 1” (WP2361, p = 0.009).
Gene expression predictive value
The predictive value of the genes that were mainly dys-
regulated due to the 24h effect of BE was investigated. 
The following endpoints were considered: disease stabili-
zation at 12 weeks, tumor shrinkage at 12 weeks, time to 
progression under BE, time to progression under chemo-
therapy, and overall survival. The magnitude of the 24h 
change in expression of the 100 most dysregulated genes 
was not significantly associated with any of the investi-
gated endpoints, after adjustment for the patients muta-
tional status.
Table  3 summarizes the predictive value of the blood 
gene expression at baseline and 24h after initiation of BE. 
Putative markers at baseline that predicted patient’s over-
all survival included Cancer susceptibility candidate 1 
(CASC1). At baseline, 142 genes were identified as puta-
tive predictive markers of tumor shrinkage at 12 weeks. 
Among those genes, there was a significant enrichment of 
the KEGG signaling pathways “Phagosome” (hsa04145) 
and “Protein digestion and absorption” (hsa04974).
Putative predictive markers from blood gene expres-
sion at 24h after initiation of treatment of the TTPBE 
included four genes enriched in the pathway “Pathways 
in cancer”. These genes were the E2F transcription fac-
tor 1 (E2F1), RAD51 recombinase (RAD51), the junction 
plakoglobin (JUP), and the microphthalmia-associated 
transcription factor (MITF). E2F1 plays a critical role 
in the control of cell cycle and acts as a tumor suppres-
sor. E2F1 was found to be associated with phenomena of 
resistance of targeted therapy in breast cancer [37]. There 
was also a significant enrichment in the signaling path-
way “Pathways in cancer” among the predictors of TS12 
at 24h: genes frizzled class receptor 5 (FZD5) and epi-
dermal growth factor (EGF). EGF encodes for a protein 
playing an important role in the cell growth, proliferation 
and differentiation. It binds with high affinity epidermal 
growth factor receptor. Its dysregulation has been associ-
ated with cancer progression [38]. Other pathways asso-
ciated with 24h predictive markers of TTPBE included 
the cancer-related pathways “Melanoma”, “Pancreatic 
cancer”, “PPAR signaling cancer”, as well as the metabo-
lism-related pathways “arginine and proline metabolism” 
and “Pyrimidine metabolism”.
All putative predictive markers of TTPBE at 24h were 
combined into a 91-gene metagene. Patients could be 
significantly classified into low-risk versus high-risk 
according to their median metagene score (HR 4.93 
[95% CI 2.34 to 10.39], log-rank test: p < 0.001) (Fig. 5, 
left panel). The median TTPBE were 2.46 (95% CI 1.54–
3.22) months vs. 6.87 (95% CI 4.14–13.31) months in the 
high-risk and low-risk populations, respectively. This 
finding was successfully validated using the KMplotter 
Fig. 3 Boxplot representation of the gene expression levels (logarithm base 2 normalized intensity) before (B) and 24h after initiation of bevaci-
zumab/erlotinib in the KEGG pathways “Hematopoietic cell lineage” (hsa04640), “ABC transporters” (hsa02010), and “Pathways in cancer” (hsa05200). 
The genes depicted in this representation belong the list of the 100 most dysregulated genes
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web tool (Fig.  5, central panel) and the external CIT 
validation dataset (Fig.  5, right panel). The predictive 
value of the metagene remained significant after adjust-
ing for the patient’s mutational status (Cox proportional 
hazards regression after adjustment for the mutational 
status: HR 2.63 [95% CI 1.87–3.70], p < 0.001). An illus-
tration of selection of responders based on the metagene 
score is provided in the Results section of the Additioanl 
file 1.
Discussion
The analysis of the immediate effect of BE in late stage 
non-squamous NSCLC reveals a series of important 
mechanisms dysregulated by the combined action of 
both therapies. Important activated pathways involved 
mechanisms such as apoptosis evasion, anti-proliferation 
and anti-angiogenesis. Interestingly, it was possible to 
detect these dysregulations directly in the blood, showing 
that potential biomarkers could be identified at the blood 
level. The changes measured in the blood over a small 
time period (24h) were of small magnitude, yet consist-
ent among patients. The use of a within-patient design 
of experiment including 2 time points before and after 
treatment helped to characterize these gene variations 
despite the relatively small sample size.
The choice of the multivariate method DCCA over 
more common gene-by-gene approaches was driven by 
the fact that DCCA addresses the problem of the iden-
tification of differentially expressed genes (in within-
patient repeated measures designs) in a multivariate 
manner. This is more statisfactory since it allows to take 
into account potential gene correlations/interactions 
using a single computationally efficient procedure. 
DCCA is an exploratory method appropriate for the pur-
pose of the current hypothesis-generating translational 
study. On the other hand, gene-by-gene approaches are 
simple and flexible and could be preferred in case of 
more complex designs or when applied to confirmatory 
analyses.
Although the magnitude of change of the most dysreg-
ulated genes over 24h was not predictive of the patient’s 
outcome, both the gene expression level at baseline and 
24h revealed a series of putative predictive genes. While 
DS12 was defined as primary clinical endpoint of the 
Fig. 4 KEGG pathway hsa05200 “Pathways in cancer”. Genes highlighted in red and green were up-regulated and down-regulated due to the 24h 
action of bevacizumab/erlotinib, respectively
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Table 3 Putative predictive markers of the patient’s response to bevacizumab/erlotinib
Gene significantly predictive of the patient’s response (p < 0.001) are reported together with the associated enriched KEGG pathways. Genes that belonged to the 
KEGG pathway “Pathways in cancer” are highlighted in italic
a TS12: tumor shrinkage at 12 weeks; DS12: disease stabilization at 12 weeks; OS: overall survival; TTPBE: time-to-progression under bevacizumab/erlotinib; TTPCT: 
time-to-progression under chemotherapy
Time Endpointa Gene symbols KEGG pathway enrich-
ment
Baseline TS12 ANO2, VPS13D, EML1, C22orf31, FERMT1, SFRP4, SUPT6H, GYS2, THBS4, ATP6V1B1, TCF21, 
ESRRB, NEUROD4, SOX15, GATA5, PRRC2B, SLC7A10, LOXL4, DISP2, TRIM7, DRD2, GPHA2, 
KCTD15, PAQR4, ANKZF1, SHROOM1, FABP7, FBXL21, KCNK5, MBL2, LY6D, VASN, FSTL5, 
MECP2, ROR2, TPT1-AS1, DCDC1, HS6ST2, HSPB7, NWD2, OR5M3, SLC35E3, UNC119B, 
OR10AB1P, UMODL1, ERN1, RNF151, CALHM1, TMPRSS12, KLK12, KRT14, LINC01551, 
NWD1, C15orf52, IL1RAPL2, TRRAP, TPK1, MYO18A, DSCR8, B3GNT6, RNA5SP430, 
C1orf132, PPAPDC1A, BTBD17, LAYN, CST9LP1, ST8SIA6-AS1, AL592528.1, RP11-337C18.4, 
GAPDHP44, HAUS7, AC010904.1, CELA3B, RP1-288M22.1, U3, CTA-929C8.7, ARSEP1, 
UBE2D3P4, RP11-38C18.2, RP11-94M14.2, AC007312.3, LINC00237, RP11-66N5.2, 
LINC01375, C1DP4, RP11-20P5.2, RP5-888M10.2, AC105443.2, FGFR1OP2P1, RP5-
855F14.2, TFAMP1, POLR3KP1, CRYGFP, TBC1D3P7, RP11-336N8.1, DCUN1D2-AS, RP11-
528G1.2, ZBTB22, TSPY15P, RP11-98G13.1, AC007679.4, KCNQ1DN, RN7SL549P, SMKR1, 
PNMA2, PI4KA, RP11-520P18.1, RP11-572M11.3, OR10J7P, RP11-331K21.1, RP11-340A13.1, 
LINC00977, RP3-368B9.2, SNORA18, HNRNPCP8, MPV17L2, NAV2-AS5, CTD-2517M22.14, 
ENPP7P5, RP11-150C16.1, HNRNPA3P10, RP11-316E14.2, RP11-566K19.5, RP11-
521O16.1, RP11-616M22.7, RP11-523L20.2, AC009120.4, RP11-106M3.3, RP11-553K8.5, 
RP11-189E14.4, RP11-520P18.5, SAMD11P1, RP11-286N3.2, SNRPCP4, RP11-343K8.3, 
AC005307.3, AC010524.4, CTB-31C7.3, WI2-80269A6.1, RP11-401N16.1, RP11-416H1.1, 
RP11-1072C15.7
Phagosome (hsa04145, 
p = 0.052) Pro-
tein digestion and 
absorption (hsa04974, 
p = 0.058)
DS12 – –
OS CASC1, HIST1H1A, FAM86C2P, Y_RNA, IGHV5-51, RP11-174G6.1, HNRNPA1P63, EEF1B2P1, 
RP3-403L10.3, RPL7P53, IGKV1-5, MRPS36P2, RP11-415I12.3, RNU6-412P, RNU6-1224P, 
RP11-61G23.2, CTD-2547H18.1, RP11-295G12.1, ZNF23
–
TTPBE BDKRB1, NRN1, LAMC1, ZNF462, LRRC43, SGSM1, FSCN2, C9orf92, RNU6-83P, RPL7AP14, 
RP11-793K1.1, RP3-433F14.1, RP1-292B18.4, AC098592.7, AC114812.8, TOMM20P1, 
LL22NC03-88E1.17, C12orf77, RP1-213J1P__B.1, LINC01038, MARK2P12, XRCC6P3, 
SHC1P1, RP3-463P15.1, LL0XNC01-116E7.2, COL4A2-AS1, CYCSP44, RAC1P8, SLMO2-
ATP5E, AF127577.12, STARD13-AS, RN7SL797P, RN7SL598P, RP11-544A12.8, RP11-
415I12.3, RP11-61G23.2, RP11-6B19.3, RP11-136F16.2, CASC18, AC002306.1, RP11-
552E10.1, RP11-361M10.3, RP11-203B7.2, RP11-475B2.1, RP11-763E3.1, RP13-516M14.2, 
RP11-820I16.1
–
TTPCT KRTAP2-3, AC090957.2, KALP, RP11-157I4.4, TSIX –
24h after initia-
tion of BE
TS12 PDZD4, SH3BP1, CALD1, SPX, MAPKBP1, MMRN1, EGF, PLOD2, ANKRD61, FZD5, CLEC1B, 
SLC39A13, SMCO4, BCRP2, TSNARE1, TDRP, TOP1MT, TPTE2P3, RNU105C, Y_RNA, 
RN7SKP257, AC006988.1, ATP5HP3, RNU6-887P, RP11-361F15.2, BANF1P2, AC099344.2, 
LINC00884, DDX39BP2, RP11-486M23.1, RP11-167N24.3, RP11-693J15.3, RP11-433P17.3
Pathways in cancer 
(hsa05200, p = 0.031)
DS12 – –
OS MYO1C, Y_RNA, DEFB134, Y_RNA, IGLV3-21, IGLC7, IGHA2, IGHA1, IGHV3-15, IGHV3-23, 
IGHV5-51, SOD1P1, AC016768.1, LINC01032, ZSCAN31, RP11-169N13.4, IGKV1-5, IGHV3-
65, IGLC4, RP11-280K24.1
–
TTPBE TNMD, TSPAN9, PRICKLE3, RAD51, MCM10, TCF3, ATP2A3, OPHN1, FBXL19, PCK2, PLTP, 
E2F1, PCYT1B, CKM, APBA1, CNTNAP1, FOXM1, KIF20A, CIT, HJURP, E2F8, KLF16, APOC1, 
ATP8B3, EPHB2, CTIF, TICRR, CTU1, CPXCR1, GRIK4, C16orf78, CKB, VKORC1, TK1, METTL7B, 
MZB1, ZNF296, RRM2, JUP, PCP2, CADM2, SLC25A22, KLHL28, GJC1, MARCH11, GAS2L1, 
MITF, HIST1H2BM, SLC25A29, SRC, MYO1C, RNU12-2P, Y_RNA, D86998.1, IGLV6-57, IGLV3-
21, IGHG1, IGHJ1, IGHV6-1, IGHV4-28, AP005482.3, RP3-407E4.4, RP11-535M15.1, IPPKP1, 
FAM195B, RP11-69C17.2, HDGFP1, SCAMP4, RD3L, TUBB4AP1, SDAD1P2, RP11-321L2.1, 
SPATA31B1P, AC005772.2, RP11-22C8.1, VN1R38P, ITGA9-AS1, NIFK-AS1, B3GNT9, RP11-
252M21.6, RN7SL60P, RP11-266N13.2, RP11-517I3.1, RP11-364C11.2, RACGAP1P, RP11-
545N8.3, RP11-81A1.3, RP11-2C24.5, AF213884.2, PRKCA-AS1, CTD-2319I12.2
Melanoma (hsa05218, 
p = 0.029) Pancreatic 
cancer (hsa05212, 
p = 0.029) PPAR signal-
ing cancer (hsa03320, 
p = 0.029) arginine and 
proline metabolism 
(hsa00330, p = 0.029
) Pathways in cancer 
(hsa05200, p = 0.029) 
Pyrimidine metabolism 
(hsa00240, p = 0.041)
TTPCT TTTY14, MTND1P4, RP11-875H7.2, LINC01021, AC008565.1, LINC01486 –
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original SAKK 19/05 trial, endpoints reflecting the activ-
ity of the treatment on the disease were more specifically 
investigated in the current translational substudy. TTPBE 
and TS12 are two endpoints which are objectively associ-
ated with the direct effect of BE. In both cases, a series 
of key predictive markers at 24h were enriched within 
the KEGG pathway “Pathways in cancer”. This pathway 
appears to play an important role both in the immediate 
effect of BE as measured in the blood, and in the predic-
tion of the response to BE.
Our findings could be validated using two independ-
ent datasets (meta-analysis from the KMplotter web 
tool and external CIT validation dataset). The combi-
nation of the key predictive markers at 24h regarding 
TTPBE into a metagene was used to generate a gene 
signature, predicting with high significance patients into 
high vs. low risk populations. This signature was suc-
cessfully validated, and could be used independently 
from the patient’s EGFR mutational status for proper 
patient selection.
Because our gene signature is independent from the 
patient’s mutational status, it can be used as predictive 
marker both in EGFR mutated and wild-type popula-
tions. BE has potential to become a standard therapy in 
NSCLC patients with EGFR mutations, and our signature 
may help to select patients which may not respond to the 
therapy despite the presence of the mutation. Inversely, 
our signature may be useful for proper selection of BE 
responders among patients not harboring EGFR activat-
ing mutation.
Our findings based on exon array data are in essence 
exploratory and future prospective confirmatory studies 
are needed to further validate the clinical relevance of 
our discovery.
Conclusion
The 24h effect of BE could be accurately monitored 
in peripheral blood using the exon array technology. 
Genes impacted by the immediate effect of BE belonged 
to key signaling pathways, according to the expected 
mechanisms of action of both bevacizumab and erlo-
tinib. Although the magnitude of change over 24h had 
no predictive value with regard to the investigated end-
points, the blood gene expression level measured 24h 
after initiation of BE could be used to predict TTPBE 
independently from the patient’s mutational status. 
Proper selection of responders to the combined targeted 
therapy BE could be monitored from blood level gene 
expression.
Abbreviations
ABC: ATP binding cassette; ADAM19: ADAM metallopeptidase domain 19; 
ATAD2: ATPase family, AAA domain containing 2; ATPase: adenosine triphos-
phatase; B: bevacizumab; BE: bevacizumab/erlotinib; BIRC3: baculoviral IAP 
repeat containing 3; BMX: BMX non-receptor tyrosine kinase; CASC1: cancer 
susceptibility candidate 1; CASC5: cancer susceptibility candidate 5; CDC42: 
cell division cycle 42; CENPE: centromere-associated protein E; CI: confi-
dence interval; CIT: Carte d’Identité des Tumeurs; CT: chemotherapy; DAPK2: 
death-associated protein kinase 2; DCCA: dually constrained correspondence 
analysis; DOCK10: dedicator of cytokinesis 10; E: erlotinib; E2F1: E2F transcrip-
tion factor 1; EGF: epidermal growth factor; EGFR: epidermal growth factor 
receptor; EKSG: ethics committee of the canton of St. Gallen; EPS8: epidermal 
growth factor receptor pathway substrate 8; FGFR: fibroblast growth factor 
receptor; FLT3: Fms-related tyrosine kinase 3; FRY: protein furry homolog; 
FZD5: frizzled class receptor 5; GBP4: guanylate binding protein 4; GEO: gene 
expression omnibus; GTPase: guanosine triphosphatase; HR: hazard ratio; 
IGF1R: insulin-like growth factor 1 receptor; IL1R1: interleukin 1 receptor, type 
I; IL1R2: interleukin 1 receptor, type II; IQR: inter-quartile range; KEGG: Kyoto 
encyclopedia of genes and genomes; JUP: junction plakoglobin; KNTC1: 
Additional file
Additional file 1.  R extension package dcca.
Fig. 5 Metagene classifier of time-to-progression under BE. The left panel displays the classification of low- versus high-risk patients based on the 
91-gene metagene. The central panel shows the classification obtained by the KMplotter online validation tool using a multigene classifier. The right 
panel shows the classification obtained by the external CIT validation dataset. Hazard ratios and log rank test p values are reported in the upper right 
corner of the each panel
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